Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ACADIA Pharmaceuticals Inc ACAD

Healthcare Biotechnology
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more

Recent & Breaking News (NDAQ:ACAD)

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 15, 2024

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 15, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 14, 2024

Grabar Law Office Investigates Claims on Behalf of Shareholders of Acadia Pharmaceuticals Inc. (ACAD)

Newsfile March 13, 2024

Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day

Business Wire March 13, 2024

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile March 13, 2024

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 13, 2024

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire March 12, 2024

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm

Newsfile March 12, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

PR Newswire March 11, 2024

Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

Business Wire March 11, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Accesswire March 9, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Newsfile March 5, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

PR Newswire March 3, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Accesswire March 1, 2024

Acadia Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference on March 6, 2024

Business Wire February 29, 2024

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview

Business Wire February 27, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Newsfile February 26, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

Accesswire February 22, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 21, 2024